To explore the effect of Modified Ruangan Decoction (加味软肝饮) on the efficacy and survival of patients with hepatocellular carcinoma and cirrhosis.

A hundred and ten patients with hepatocellular carcinoma and cirrhosis were divided into two groups by random number table method. The control group (55 cases) was treated with transcatheter arterial chemoembolization (TACE), and the observation group (55 cases) was treated with Modified Ruangan Decoction on this basis. Two groups were treated continuously for 3 months. The clinical effects of the two groups were recorded and compared. Liver function test kit was used to detect the liver function indexes［alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBil) ］of the patients before and after treatment. The tumor markers of alpha-fetoprotein anisoplast 3 (AFP-L3), enolase-1 (ENO1) and abnormal prothrombin (PIVKA-Ⅱ) were detected by enzyme-linked immunosorbent assay. The adverse events were recorded and compared, including gastrointestinal reactions, renal dysfunction, peripheral nerve injury and myelosuppression. After treatment, the patients were followed up for 1 to 3 years, and the survival rate of the two groups was recorded and compared.

The disease control rate of the observation group was higher than that of the control group (P<0.05) . In terms of the specific concentration levels of ALT, AST and TBil, there was no difference between the two groups before treatment (P>0.05) . After treatment, the specific concentration levels of ALT, AST and TBil of the two groups decreased (P<0.05), and compared with those in the control group, these indicators were significantly lower in the observation group (P<0.05) . In terms of the specific concentration levels of AFP-L3, ENO1 and PIVKA-Ⅱ, there was no difference between the two groups before treatment (P>0.05) . After treatment, the specific concentration levels of AFP-L3, ENO1 and PIVKA-Ⅱ in the two groups decreased (P<0.05), and compared with those in the control group, these indexes were significantly lower in the observation group (P<0.05) . After treatment, the incidence of adverse reactions in observation group was lower than that in control group (P<0.05) . There was no difference in the survival rate between the two groups during 1-year follow-up (P>0.05), and the survival rate in the 2-year and 3-year follow-up groups was higher than that in the control group (P<0.05) .

Modified Ruangan Decoction has good efficacy in patients with hepatocellular carcinoma and cirrhosis. It can improve liver function and reduce tumor marker levels, prolong the survival period, and is highly safe.